The potent and highly selective RET* inhibitor BLU-667 was well-tolerated and exhibited promising clinical activity among patients with advanced, RET-altered solid cancers that progressed despite multikinase inhibitor therapy, according to data presented at AACR 2018.
A dual-inhibition immunotherapeutic regimen consisting of the highly selective IDO1* inhibitor epacadostat and the PD-L1** inhibitor durvalumab was safe for advanced solid tumours, according to findings from the ongoing ECHO-203*** study presented at AACR 2018.
The addition of pembrolizumab to a pemetrexed-platinum chemotherapy regimen improved overall survival (OS) and progression-free survival (PFS) in patients with advanced non-squamous non-small-cell lung cancer (NSCLC), findings from the phase III KEYNOTE-189* trial show.
Pembrolizumab delivered intravenously every 3 weeks for 1 year extended recurrence-free survival (RFS) in patients with resected stage III melanoma, according to results of the KEYNOTE-054/EORTC 1325-MG* trial.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacist - Malaysia digital copy today!
Osteoarthritis (OA) is the most common condition affecting the joints. Dr Lee Eu Jin, an Orthopaedic Surgeon from Liberty Orthopaedic Clinic at Mount Elizabeth Medical Centre, Singapore, shares his insights with Pearl Toh on how to manage OA in the primary care setting.
The use of aspirin for primary prevention in patients without known cardiovascular diseases (CVDs) significantly reduces the risk of myocardial infarction (MI) but increases that of major bleeding and haemorrhagic stroke, according to a meta-analysis.